Literature DB >> 15503302

c-Myc localization within the nucleus: evidence for association with the PML nuclear body.

Kelly P Smith1, Meg Byron, Brenda C O'Connell, Rose Tam, Christoph Schorl, Isil Guney, Lisa L Hall, Pooja Agrawal, John M Sedivy, Jeanne B Lawrence.   

Abstract

Definitive localization of c-Myc within the nucleus is important to fully understand the regulation and function of this oncoprotein. Studies of c-Myc distribution, however, have produced conflicting results. To overcome technical challenges inherent in c-Myc cytology, we use here three methods to visualize c-Myc and in addition examine the impact of proteasome inhibition. EYFP or HA-tagged Myc was reintroduced by stable transfection into myc null diploid rat fibroblasts, replacing endogenous Myc with tagged Myc expressed at or near normal levels. This tagged Myc is shown to functionally replace the endogenous Myc by restoration of normal cell morphology and growth rate. We were able to confirm key findings using antibodies to the endogenous c-Myc and/or its partner, Max. Contrary to some published reports, by all three methods the c-Myc protein in rat fibroblasts distributes predominantly throughout the nucleus in a dispersed granular pattern, avoiding the nucleolus. Importantly, however, several findings provide evidence for an unanticipated relationship between c-Myc and PML nuclear bodies, which is enhanced under conditions of proteasome inhibition. Evidence of Max concentration within PML bodies is shown both with and without proteasome inhibition, strengthening the relationship between PML bodies and Myc/Max. Some accumulation of Myc and Max in nucleoli upon proteasome inhibition is also observed, although co-localization of ubiquitin was only seen with PML bodies. This work provides a comprehensive study of c-Myc distribution and also presents the first evidence of a relationship between turnover of this oncoprotein and PML nuclear bodies, known to break down in certain cancers. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15503302     DOI: 10.1002/jcb.20273

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  8 in total

Review 1.  PML nuclear bodies.

Authors:  Valérie Lallemand-Breitenbach; Hugues de Thé
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-04-21       Impact factor: 10.005

2.  mTOR complex 1 controls the nuclear localization and function of glycogen synthase kinase 3β.

Authors:  Stephen J Bautista; Ivan Boras; Adriano Vissa; Noa Mecica; Christopher M Yip; Peter K Kim; Costin N Antonescu
Journal:  J Biol Chem       Date:  2018-07-30       Impact factor: 5.157

3.  Cellular senescence and protein degradation: breaking down cancer.

Authors:  Xavier Deschênes-Simard; Frédéric Lessard; Marie-France Gaumont-Leclerc; Nabeel Bardeesy; Gerardo Ferbeyre
Journal:  Cell Cycle       Date:  2014-05-27       Impact factor: 4.534

4.  MYC and Prostate Cancer.

Authors:  Cheryl M Koh; Charles J Bieberich; Chi V Dang; William G Nelson; Srinivasan Yegnasubramanian; Angelo M De Marzo
Journal:  Genes Cancer       Date:  2010-06

5.  Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis.

Authors:  Bora Gurel; Tsuyoshi Iwata; Cheryl M Koh; Robert B Jenkins; Fusheng Lan; Chi Van Dang; Jessica L Hicks; James Morgan; Toby C Cornish; Siobhan Sutcliffe; William B Isaacs; Jun Luo; Angelo M De Marzo
Journal:  Mod Pathol       Date:  2008-06-20       Impact factor: 7.842

6.  Arsenic trioxide disrupts glioma stem cells via promoting PML degradation to inhibit tumor growth.

Authors:  Wenchao Zhou; Lin Cheng; Yu Shi; Susan Q Ke; Zhi Huang; Xiaoguang Fang; Cheng-wei Chu; Qi Xie; Xiu-wu Bian; Jeremy N Rich; Shideng Bao
Journal:  Oncotarget       Date:  2015-11-10

7.  Chronic radiation exposure of neuroblastoma cells reduces nMYC copy number.

Authors:  Manu Gnanamony; Reuben Antony; Karen S Fernández; Libes Jaime; Julian Lin; Pushpa A Joseph; Christopher S Gondi
Journal:  Oncol Lett       Date:  2017-07-21       Impact factor: 2.967

8.  The Mechanism by Which MYCN Amplification Confers an Enhanced Sensitivity to a PCNA-Derived Cell Permeable Peptide in Neuroblastoma Cells.

Authors:  Long Gu; Peiguo Chu; Robert Lingeman; Heather McDaniel; Steven Kechichian; Robert J Hickey; Zheng Liu; Yate-Ching Yuan; John A Sandoval; Gregg B Fields; Linda H Malkas
Journal:  EBioMedicine       Date:  2015-11-10       Impact factor: 8.143

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.